Résumé
Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.
langue originale | Anglais |
---|---|
Numéro d'article | 2412874 |
journal | OncoImmunology |
Volume | 13 |
Numéro de publication | 1 |
Les DOIs |
|
état | Publié - 1 janv. 2024 |
Modification externe | Oui |